Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept in transfusion-dependent beta-thalassemia
NCT02604433Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- May 2016
- Primary completion
- Jan 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 15
01
Overview
A Phase 3 trial of luspatercept in beta thalassemia, sponsored by Celgene Corporation. Started May 2016; status: completed.
02
Drugs
luspatercept
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT02604433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02604433.